Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Other Non-Current Assets (2023 - 2026)

ArriVent BioPharma has reported Other Non-Current Assets over the past 4 years, most recently at $69000.0 for Q1 2026.

  • Quarterly results put Other Non-Current Assets at $69000.0 for Q1 2026, down 60.8% from a year ago — trailing twelve months through Mar 2026 was $69000.0 (down 60.8% YoY), and the annual figure for FY2025 was $190000.0, up 50.79%.
  • Other Non-Current Assets reached $69000.0 in Q1 2026 per AVBP's latest filing, down from $190000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.7 million in Q4 2023 and bottomed at $69000.0 in Q1 2026.
  • Median Other Non-Current Assets over the past 4 years was $151000.0 (2024), compared with a mean of $431100.0.
  • The largest annual shift saw Other Non-Current Assets crashed 95.39% in 2024 before it soared 283.2% in 2025.
  • Over 4 years, Other Non-Current Assets stood at $2.7 million in 2023, then plummeted by 95.39% to $126000.0 in 2024, then skyrocketed by 50.79% to $190000.0 in 2025, then crashed by 63.68% to $69000.0 in 2026.
  • Business Quant data shows Other Non-Current Assets for AVBP at $69000.0 in Q1 2026, $190000.0 in Q4 2025, and $180000.0 in Q3 2025.